Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Breaux Castleman sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the transaction, the director now directly owns 25,183 shares of the company’s stock, valued at $1,510,980. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of NASDAQ IONS opened at $58.96 on Wednesday. The company has a current ratio of 9.91, a quick ratio of 9.83 and a debt-to-equity ratio of 0.51. Ionis Pharmaceuticals Inc has a twelve month low of $39.32 and a twelve month high of $73.09. The stock has a 50 day moving average of $56.72 and a two-hundred day moving average of $56.41. The stock has a market cap of $8.18 billion, a P/E ratio of 53.60 and a beta of 1.68.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.23). Ionis Pharmaceuticals had a net margin of 16.79% and a return on equity of 12.50%. The firm had revenue of $133.00 million during the quarter, compared to analysts’ expectations of $161.59 million. During the same quarter in the prior year, the firm posted $0.62 EPS. Ionis Pharmaceuticals’s quarterly revenue was down 55.2% compared to the same quarter last year. As a group, research analysts predict that Ionis Pharmaceuticals Inc will post -0.48 earnings per share for the current year.
A number of equities analysts have recently commented on IONS shares. Oppenheimer lowered their price objective on Ionis Pharmaceuticals from $77.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. JPMorgan Chase & Co. boosted their price objective on Ionis Pharmaceuticals from $58.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, March 9th. Citigroup boosted their price objective on Ionis Pharmaceuticals from $71.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Morgan Stanley boosted their price objective on Ionis Pharmaceuticals from $48.00 to $51.00 and gave the stock an “underweight” rating in a research report on Thursday, May 7th. Finally, BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $73.13.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Featured Article: 52 Week Highs
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.